-
Esperion Therapeutics Inc (NASDAQ: ESPR) shares
fell 37.87 percent to touch a new 52-week low of $10.05 after failing to reach an agreement with the FDA regarding a definitive
approval path for its ETC-1002, a cholesterol-lowering pill. JP Morgan downgraded Esperion Therapeutics from Overweight to
Neutral and lowered the price target from $50.00 to $15.00, while Credit Suisse also downgraded the stock from Neutral to
Underperform and lowered the price target from $23.00 to $10.00.
-
Lipocine Inc (NASDAQ: LPCN) shares touched a new
52-week low of $2.98 following announcement of a Complete Response Letter from the FDA. The response letter noted deficiencies
in dosing algorithm on label.
-
AEGON N.V. (ADR) (NYSE: AEG) shares touched a new
52-week low of $3.912. Barclays downgraded Aegon from Equal-weight to Underweight.
-
Galena Biopharma Inc (NASDAQ: GALE) shares fell
84.06 percent to reach a new 52-week low of $0.324 after the company revealed it discontinued NeuVax™ (nelipepimut-S) Phase 3
PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with
NeuVax Treatment) clinical study. The company added that on June 27, the IDMC recommended that the PRESENT trial be stopped due
to futility.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.